|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0178602,
umls-concept:C0205466,
umls-concept:C0332161,
umls-concept:C0473169,
umls-concept:C0524910,
umls-concept:C0556985,
umls-concept:C0796545,
umls-concept:C0871261,
umls-concept:C1274040,
umls-concept:C1521801,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2603343,
umls-concept:C2911692
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-8-19
|
|
pubmed:abstractText |
SUMMARY: Beside substantial progress in treatment of chronic hepatitis C (CHC) particular patients (genotype 1/4, high viral load, previous nonresponse, cirrhosis) remain difficult to treat. The aim of our pilot randomized study was to compare efficacy and tolerability of standard doses of Peginterferon alpha-2b + ribavirin with higher doses of Peginterferon alpha-2b administered twice weekly + ribavirin. Sixty-five outpatients with CHC were subsequently enrolled. Group A (n = 22) received recommended doses of Peginterferon alpha-2b and group B (n = 43), received high doses twice weekly. Groups were comparable for baseline characteristics. All genotype 1/4 patients had high baseline viraemia. Sustained virological response (SVR) was significantly higher in group B among naïve patients (72%vs 25%, P = 0.024). A significantly higher rate of SVR was observed in group B both considering only genotype 1/4 patients, (46%vs 13%, P = 0.03) and grouping together genotype 1/4 naive and relapsers (57%vs 11%, P = 0.039). Discontinuation rate was 32% (7 of 22) in group A and 21% (9 [corrected] of 43) in group B. Our response rates are the highest reported for genotype 1/4 with high viraemia. Our pilot study supports the need of randomized studies to evaluate both viral kinetics and efficacy of high dose and twice weekly administration of Peginterferon alpha-2b in genotype 1/4 patients with high viraemia who may need personalized treatment schedules.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1352-0504
|
|
pubmed:author |
pubmed-author:AzzaroliFF,
pubmed-author:Bacchi ReggianiM LML,
pubmed-author:BrillantiSS,
pubmed-author:ColecchiaAA,
pubmed-author:FelettiVV,
pubmed-author:GiovanelliSS,
pubmed-author:LodatoFF,
pubmed-author:MazzellaGG,
pubmed-author:MontagnaniMM,
pubmed-author:MuratoriRR,
pubmed-author:RodaEE,
pubmed-author:TaméM RMR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
536-42
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16108771-Adult,
pubmed-meshheading:16108771-Antiviral Agents,
pubmed-meshheading:16108771-Dose-Response Relationship, Drug,
pubmed-meshheading:16108771-Drug Administration Schedule,
pubmed-meshheading:16108771-Drug Interactions,
pubmed-meshheading:16108771-Drug Therapy, Combination,
pubmed-meshheading:16108771-Female,
pubmed-meshheading:16108771-Hepatitis C, Chronic,
pubmed-meshheading:16108771-Humans,
pubmed-meshheading:16108771-Interferon-alpha,
pubmed-meshheading:16108771-Male,
pubmed-meshheading:16108771-Middle Aged,
pubmed-meshheading:16108771-Pilot Projects,
pubmed-meshheading:16108771-Polyethylene Glycols,
pubmed-meshheading:16108771-Recombinant Proteins,
pubmed-meshheading:16108771-Ribavirin,
pubmed-meshheading:16108771-Treatment Outcome,
pubmed-meshheading:16108771-Viral Load
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study.
|
|
pubmed:affiliation |
Department of Internal Medicine & Gastroenterology, University of Bologna, Bologna, Italy. francesca.lodato@inwind.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
